Summary of Product Characteristics Patient Leaflet Safety Information AAA | Print

US RESIDENTS | This site is intended for healthcare professionals outside the US.

MOA|Trial Design|Efficacy|Safety|Dosing and Adminstration

Signifor Is the First Approved Pituitary-Targeted Medical Therapy for Cushing's Disease

Signifor, a novel multireceptor-targeted somatostatin analogue, binds with high affinity to 4 of the 5 ssts, with the highest affinity for sst5, resulting in inhibition of adrenocorticotropic hormone (ACTH) secretion. Signifor represents the first specific treatment for ACTH-secreting pituitary adenomas and is the first approved medical treatment for Cushing's disease.1

In this section you will find information about:

Signifor is indicated for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.1

References: 1. Signifor Summary of Product Characteristics. Novartis Pharma AG. 2. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914-924. 3. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357(9258):783-791.

Cushing's Disease

Cushing's disease is a rare hormone
disorder. Recent statistics indicate
the annual incidence is somewhere
between 1 and 10 new cases per
million.3

Click here
Disclaimer: This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country specific and may contain information that is outside the approved indications in the country in which you are located.

About Novartis Oncology Contact Us Site Map Use of Web site is governed by the Terms of Use and Privacy Policy
© Novartis AG

Theme Template for Bootstrap